Skip to main content

Table 2 Therapeutic strategies targeting tau in AD drug development

From: Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

Therapeutic strategy

Drug

Mechanism

Sponsor

Study population

Admin

Phase

Results

Clinical Trial Identifier

Start date

Estimated end date

Active immunotherapy

AADvac1

Active vaccine

Axon Neuro-

science SE

Mild AD

IV

II

Completed

NCT02579252

2016 Mar

2019 Jun

ACI-35

Active vaccine

AC Immune SA, Janssen

Early AD

IV

I/II

Recruiting

NCT04445831

2019 Jul

2023 Oct

Passive immunotherapy

RG7345

(RO6926496)

Monoclonal antibody

Discontinued

Healthy

IV

I

Completed

NCT02281786

2015 Jan

2015 Oct

BIIB076

(NI-105)

Monoclonal

antibody

Biogen

Healthy and AD

IV

I

Completed

NCT03056729

2017 Feb

2020 Mar

Semorinemab

(RO7105704)

Monoclonal antibody

Genentech

Mild AD

IV

II

Completed

NCT03289143

2017 Oct

2021 Jan

  

Genentech

Moderate AD

IV

II

Active, not recruiting

NCT03828747

2019 Jan

2023 Oct

Tilavonemab

(ABBV-8E12)

Monoclonal antibody

AbbVie

Early AD

IV

II

Completed

NCT02880956

2016 Oct

2021 Jul

  

AbbVie

Early AD

IV

II

Active, not recruiting

NCT03712787

2019 Mar

2021 Jul

Zagotenemab

(LY3303560)

Monoclonal antibody

Eli Lilly

Early AD

IV

II

Active, not recruiting

NCT03518073

2018 Apr

2021 Oct

Gosuranemab

(BIIB092)

Monoclonal antibody

Biogen,

Mild AD

IV

II

Terminated

NCT03352557

2018 May

2021 Aug

PNT001

Monoclonal antibody

Pinteon Therapeutics

Healthy

IV

I

Completed

NCT04096287

2019 Sept

2021 Feb

Lu AF87908

Monoclonal

antibody

H. Lundbeck

Healthy and AD

IV

I

Recruiting

NCT04149860

2019 Sept

2022 Jul

JNJ-63733657

Monoclonal antibody

Janssen

Early AD

IV

II

Recruiting

NCT04619420

2021 Jan

2025 Mar

E2814

Monoclonal

antibody

Eisai

Mild to moderate AD

IV

I/II

Recruiting

NCT04971733

2021 Jun

2024 Apr

Bepranemab

(UCB0107)

Monoclonal antibody

Hoffmann La Roche, UCB S.A

Mild cognitive impairment or mild AD

IV

II

Recruiting

NCT04867616

2021 Jun

2025 Nov

  1. AD, Alzheimer’s disease; Admin, Route of administration; IV, intravenous